Trial · NCT06681012
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care pro
- Status
- Recruiting
- Sponsor
- Devintec Sagl
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 330 participants (planned)
- Start
- Oct 22, 2024
- Primary completion
- July 2027
- Conditions
- Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Summary
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease, but imposes a significant burden on society, entailing a decrease in patients' Quality of Life (QoL), elevated rates of psychological comorbidities and loss of work productivity, which might be the greatest in subjects with IBS-D, for whom the fear of incontinence in a social situation can be especially debilitating.
Interventions
- Gelsectan® Device
- Placebo Drug
Locations
4 countries: Belgium, France, Italy, Spain.
| Facility | City | Country |
|---|---|---|
| University Hospitals Leuven (UZ Leuven) | Leuven | Belgium |
| Hôpital Avicenne | Bobigny | France |
| CHU de Rouen | Rouen | France |
| IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola | Bologna, BO | Italy |
| IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation | Milan | Italy |
| AOU Federico II di Napoli | Naples | Italy |
| Azienda Ospedale Università Padova | Padova | Italy |
| Fondazione IRCCS Policlinico San Matteo | Pavia | Italy |
| Azienda Ospedaliero Universitaria Pisana (AOUP) | Pisa | Italy |
| S. Andrea University Hospital | Roma | Italy |
| Hospital Universitario Vall d´Hebron | Barcelona | Spain |
| Hospital Universitario Ramón y Cajal | Madrid | Spain |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.